THE UNIVERSITY OF BIRMINGHAM Patent applications |
Patent application number | Title | Published |
20160136287 | CONJUGATED VACCINE - The present invention provides a composition for provoking an immune response in a patient to an autoantigen target, the composition comprising the target conjugated a carrier polypeptide. | 05-19-2016 |
20160106862 | Re-Directed Immunotherapy - The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells. | 04-21-2016 |
20150376701 | BIOMARKERS OF AUTOIMMUNE AND/OR CHRONIC DISEASES ASSOCIATED WITH JOINT INFLAMMATION - The present invention relates to methods and uses of FcRL4 expression and optionally RANKL expressing B cells as biomarkers and therapeutic target for treatment of an autoimmune and/or chronic diseases associated with joint inflammation, in particular Rheumatoid Arthritis (RA). | 12-31-2015 |
20150301041 | ASSAY METHOD - A method of determining the likelihood of a patient developing rheumatoid arthritis (RA) is provided, which relies on the use of AdipoR1 and/or AdipoR2 in leukocytes as prognostic markers. The method may comprise determining the expression of A dipoR1 and/or AdipoR2 in leukocytes in a sample from said patient. The method may be used for screening, within a population, one or more patients likely to develop RA. | 10-22-2015 |
20150250868 | Re-Directed Immunotherapy - The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells. | 09-10-2015 |
20150246037 | TREATMENT FOR NEURODEGENERATION - Provided is a method of treating and/or preventing Wolfram Syndrome (WS)-related neurodegeneration (i.e. of Wolfram Syndrome-Associated Neuronal Degeneration), by increasing the expression and/or functional activity of p21. A method of screening for pharmacological agents useful in treating and/or preventing such conditions is also provided. | 09-03-2015 |
20150060371 | Reactor for Substrate Oxidation - A reactor and process for the oxidation of substrates, comprising: a first reaction chamber configured to dissolve substrates in a fluid, the first reaction chamber comprising a linking outlet; the linking outlet being connected to a tubular reaction chamber downstream of the first reaction chamber, conditions in the first reaction chamber being subcritical for the fluid, and conditions in the tubular reaction chamber being supercritical for the fluid carrying the dissolved substrates | 03-05-2015 |
20150051137 | PEPTIDE AND USES THEREFOR - Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N′-SVTEQGAELSNEER-C′ {SEQ ID NO: 1) or an analogue thereof that inhibits T cell migration. Also provided is the peptide or its analogue for use in the methods of treatment: and/or prophylaxis of said condition. | 02-19-2015 |
20140308458 | Method for Producing Particulate Clusters - A method for producing particulate clusters comprises passing a core through an array of matrix-supported coating particles. Particulate clusters produced by the method may find application as catalytic particles, components of novel electronic and photonic materials and sensors, and as binding sites for protein molecules in biochips. | 10-16-2014 |
20140295550 | HLA PEPTIDE THERAPY - The invention provides polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof. The polypeptides, derivatives and analogues can be used to treat or prevent allosensitisation, such as the treatment or prevention of allograft rejection. | 10-02-2014 |
20140295425 | Diagnosis for Alzheimer's Disease - The present invention relates to diagnosis and monitoring of Alzheimer's disease in the live subject. More particularly, the invention relates to methods involving the measurement of differential gene expression in non-neuronal cells taken from human subjects suspected of having Alzheimer's disease wherein the genes to be measured are genes within the m TOR signalling pathway. | 10-02-2014 |
20140194466 | PERHEXILINE FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY (HCM) - The invention relates to perhexiline, or a pharmaceutically acceptable salt or enantiomer thereof, for use in the treatment of hypertrophic cardiomyopathy, as well as to a method of treating HCM, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt or enantiomer thereof, to treat said HCM. The invention further relates to a treatment programme for treating HCM, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HCM or the symptoms thereof. | 07-10-2014 |
20140159971 | MULTI-OUTPUT ANTENNA - A reconfigurable multi-output antenna ( | 06-12-2014 |
20140004081 | Re-Directed Immunotherapy | 01-02-2014 |
20130307742 | BALANCED ANTENNA SYSTEM - The invention relates to a balanced antenna system comprising a radiator connected via a matching circuit to a balun. In certain embodiments, the radiator comprises a first radiating element and a second radiating element and the matching circuit comprises a first impedance-matching circuit connected to the first radiating element and a second impedance-matching circuit connected to the second radiating element. The first and second matching circuits may be identical and are connected through the balun to a single port. To minimise the component count, the design of the matching circuit and balun is co-optimised. | 11-21-2013 |
20130295231 | COMESTIBLE PRODUCT - The application relates to comestible products comprising acid gellable hydrocolloids, such as low acyl gellan gum. These are used for appetite suppression. On ingesting the product the hydrocolloid gels in the stomach. Mixed hydrocolloids, such as pectin and gellan gums are also provided. | 11-07-2013 |
20130231257 | BIOMARKER - A method of diagnosing or determining the degree of an arterial aneurysm, especially an abdominal aortic aneurysm, which comprises determining the presence or level of interleukin-1α (IL-1aα) in a serum or plasma sample. | 09-05-2013 |
20130195883 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS - The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method. | 08-01-2013 |
20120242558 | RECONFIGURABLE ANTENNA - A reconfigurable antenna comprises two or more mutually coupled radiating elements and two or more impedance-matching circuits ( | 09-27-2012 |
20110038881 | PROGNOSTIC ASSAY FOR DETERMINING T CELL RESPONSE TO HLA ANTIGENS AND USE THEREOF IN FIELD OF TISSUE TRANSPLANTATION - The invention provides an in vitro method of determining whether an individual is at risk of, or undergoing, graft damage or rejection of immune origin and/or damage of immune origin to non-graft tissue using polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof. | 02-17-2011 |
20100279324 | Assay For Detecting Mycobacterial Infection - Methods for assessing a mycobacterial infection in a subject comprise exposing at least one CD1 molecule or analogue to mycolic acid or a mycolic acid analogue, subsequently incubating the at least one CD1 molecule or analogue with a sample comprising at least one T cell isolated from the subject, and measuring the T cell response and/or the number of mycolic acid specific T cells present in the T cell sample. | 11-04-2010 |
20100104876 | PIEZOELECTRIC COMPOSITE MATERIAL - The present invention provides a method for producing a composite material comprising an array of piezoelectric fibres, the method comprising: (a) providing: (a1) a plurality of first strips comprising a piezoelectric material or a precursor to a piezoelectric material, and a first carrier, and (a2) a plurality of second strips comprising a decomposable material, and a second carrier; (b) placing said pluralities of said first and second strips alternately on top of one another to form a stack in which at least a portion of said first strips is separated from adjacent first strips by a second strip; (c) a heating step comprising heating said stack to remove said first and second carriers and said decomposable material; (d) impregnating said stack with a filler material to form a composite stack of piezoelectric strips; and (e) cutting said stack to form a composite material comprising an array of piezoelectric fibres. In an alternative method the cutting (e) is performed before the heating step (c). The methods allow for the production of fibre arrays with mean fibre spacing of 5 ym or less. | 04-29-2010 |
20090297475 | CYSTEINE DIOXYGENASE POLYMORPHISMS - The invention relates to the detection and identification of polymorphisms in cysteine dioxygenase (CDO) for the use of that diagnosis to identify a propensity in a patient towards rheumatoid arthritis and/or to have side effects with a number of drugs, to nucleic acid and isolated proteins encoding the polymorphisms, to assays for CDO activity and for the identification of compounds affecting CDO activity, and additionally to use of interferon-γ optionally in combination with different compounds, to treat rheumatoid arthritis. | 12-03-2009 |
20090105343 | Cancer Therapy And Medicaments Therefor - The present invention relates to a novel cancer therapy, particularly, but not exclusively, to a prostate, bladder and breast cancer therapy and to Compositions and medicaments for use in said therapy. In one aspect there is provided a method of treating a patient afflicted with cancer comprising administering to the patient a therapeutically effective amount of a nuclear receptor ligand and an HDAC (histone deacetylases) inhibitor wherein said nuclear receptor ligand is not a ligand for the vitamin D receptor. | 04-23-2009 |